Drugs / Hemay020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02467569 | Jul 2015 → Dec 2017 | non-small cell lung carcinoma | Tianjin Hemay Pharmaceutical Co., Ltd | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hemay020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02467569 ↗ |
| Action | Inhibit | “irreversible Epidermal Growth Factor Receptor Inhibitor Hemay020” NCT02467569 ↗ |
| Route | Oral | “Hemay020 capsules will be taken orally” NCT02467569 ↗ |
| Target | EGFR | “irreversible Epidermal Growth Factor Receptor Inhibitor Hemay020” NCT02467569 ↗ |